# Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

> **NCT04690556** · PHASE3 · COMPLETED · sponsor: **Lupin Ltd.** · enrollment: 600 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** LUBT010 (proposed ranibizumab biosimilar)
- **DRUG:** Lucentis (ranibizumab)

## Key facts

- **NCT ID:** NCT04690556
- **Lead sponsor:** Lupin Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-14
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04690556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04690556, "Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04690556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*